Press Releases
Provides updates on vagus nerve stimulation (VNS) program and expectations for 2025 FREMONT, Calif. – December 23, 2024 – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders. Dear Fellow Shareholders: As we conclude 2024 and look forward to 2025, I’d […]
Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT FREMONT, Calif.– November 14, 2024 – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus […]
FREMONT, Calif. – November 14, 2024– Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation (VNS) device. The study is being conducted by The Feinstein Institute of Bioelectronic […]
Patents cover methods used to identify key treatment points and dynamically personalize simulation FREMONT, Calif. – November 12, 2024– Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicinal devices, announced today that it has validated two granted European Patent Office (EPO) patents in Great Britain, Germany, and France. The […]
– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST – FREMONT, Calif. – November 7, 2024 – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be […]
FREMONT, Calif. – October 29, 2024– Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject has been enrolled in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation device. The study, being run by The Feinstein Institute of Bioelectronic […]
– Presentation will highlight Tivic Health’s recent advancements in vagus nerve stimulation – SAN FRANCISCO – October 24, 2024– Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst’s […]
SAN FRANCISCO – (Business Wire) – September 18, 2024 – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it has received approval from The Feinstein Institutes’ Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation (“ncVNS”) […]
Partners with leading growth strategy firm, Fletcher Spaght SAN FRANCISCO – (Business Wire) – September 17, 2024 – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght (“FSI”), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy […]
Kimberly Bambach, Ms. Wolf’s predecessor, continues with Tivic as advisor focused on strategic transactions and special projects SAN FRANCISCO – (Business Wire) – September 13, 2024 – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief […]